Exclusive Summary

• Differentiated Best-in-Class Potential: UB954 is an irreversible, covalent TEAD1/3/4 selective inhibitor that demonstrates superior in vivo tumor growth inhibition (TGI) and target binding compared to non-covalent or pan-TEAD competitors.
• Excellent Safety Window and Dosing Flexibility: It shows zero off-target hits across a 468-kinase panel, features a de-risked clinical profile (US IND approved, Phase 1 dose escalation completed in China with no DLTs), and supports intermittent dosing to mitigate toxicity.
• Massive Combination and Expansion Potential: Beyond its strong single-agent activity in rare tumors (MPM/EHE), it demonstrates highly synergistic effects with EGFR (Osimertinib) and KRAS (MRTX1133) inhibitors in vitro/in vivo, coupled with excellent BBB penetration, making it highly attractive for MNCs targeting resistance pathways in lung and pancreatic cancers.
• Solid IP and Read-to-Partner Status: Supported by a comprehensive global PCT patent portfolio (covering compound and crystal forms) and a clear US/China clinical trajectory, making it an ideal asset for global license-out or co-development.

Asset Materials

Contact Us for Full Materials